New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
17:55 EDTMNK, QCORQuestcor's Acthar risks not included in Mallinckrodt's merger proxy, NYT says
Risks regarding the increase of adverse events related to Questcor's (QCOR) drug Acthar need to be considered by Mallinckrodt's (MNK) shareholders. Those risks were not included in last month's merger proxy, reports the New York Times. Reference Link
News For MNK;QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
17:43 EDTMNKOrexigen in manufacturing pact with Mallinckrodt for naltrexone
Subscribe for More Information
May 28, 2015
09:24 EDTMNKJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use